Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung Innate Defenses in the Fetus and Newborn Infant

胎儿和新生儿巨噬细胞成熟和肺先天防御的聚糖-凝集素受体调节

• 批准号: 9979752
• 负责人: Victor Nizet
• 金额: $ 43.86万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-17 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9979752
• 关键词: Adult; Alveolar Macrophages; Amniotic Fluid; Area; Aspirate substance; Autoantigens; Bacteria; Binding; Birth; Carbon; Cell Ontogeny; Cells; Characteristics; Childhood; Collaborations; Communicable Diseases; Competence; Data; Defect; Detection; Development; Disease; Elements; Environment; Epithelial; Epithelium; Equation; Exposure to; FDA approved; Fetal Lung; Fetus; Genetic; Genetic Models; Glycobiology; Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Hemolysin; Human; ITIM; Immune; Immune Evasion; Immune Tolerance; Immune response; Immune signaling; Immune system; Immunity; Immunocompetence; Immunoglobulins; Immunosuppression; In Vitro; Infant; Infection; Infectious Agent; Inflammation; Inflammatory; Inhalation; Injury; Knockout Mice; Laboratories; Lectin Receptors; Leukocytes; Light; Lung; Lung Inflammation; Macrophage Activation; Mammalian Cell; Measures; Microbe; Molecular; Molecular Mimicry; Mothers; Mouse Protein; Mus; Natural Immunity; Neonatal; Neutrophil Activation; Neutrophil Infiltration; Newborn Infant; Organ; Pathogenesis; Pattern; Perinatal; Phagocytes; Pharmaceutical Preparations; Pharmacology; Physicians; Pneumonia; Polysaccharides; Predisposition; Pregnancy; Premature Infant; Prevention; Principal Investigator; Proteins; Pulmonary Inflammation; Race; Regulation; Regulatory Pathway; Research Personnel; Risk; Role; Scientist; Sepsis; Sialic Acids; Side; Signal Pathway; Signal Transduction; Specialist; Streptococcal Infections; Streptococcus Group B; Streptococcus pneumoniae; Surface; Testing; Time; Urine; Virulence; alveolar epithelium; arm; capsule; chronic infection; early onset; fetal; host-microbe interactions; immune activation; immune function; immunoregulation; improved; in utero; in vivo; innovation; insight; leukocyte activation; lung development; lung injury; lung maturation; macrophage; mature animal; mimicry; mortality; mutant; neonatal immune system; neonatal immunity; neonate; novel; pathogen; pathogenic microbe; patient population; perinatal period; pneumonia model; prevent; receptor; response; screening; sialic acid binding Ig-like lectin; sialic acid receptor; sialoadhesin; sugar; targeted treatment; therapeutic evaluation; tool; translational approach; treatment group; uptake

Summary The fetal and neonatal immune systems maintain a state of tolerance during pregnancy. However the moment that infants are born, their immature immune system must defend against the sudden onslaught of microbial pathogens present in the environment. Unfortunately for many, the transition from tolerance to protection is slow, providing windows of opportunity for specific infectious organisms. This susceptibility is best illustrated by group B Streptococcus (GBS), which is the most common pathogen in neonates but rarely leads to disease in healthy adults. Neonates are first exposed to GBS around delivery, as GBS frequently colonizes the birth canal. Despite efforts around screening and maternal treatment, GBS continues to be the major cause of neonatal pneumonia and early onset sepsis. To discover the mechanisms of GBS infection and immunity in the immature lung, we developed a novel mouse GBS pneumonia model. Adult mice clear GBS within 24 h, quickly resolve the initial lung inflammation, and universally survive GBS infection. However, neonatal mice fail to efficiently kill GBS, develop persistent lung inflammation and injury, and can die from GBS infection. Macrophages, the first line of defense in adult lungs, are immature in neonates making them vulnerable to inhaled and aspirated bacteria including GBS. Our preliminary studies show that immature neonatal lung macrophages fail to mount a normal immune response against GBS or kill phagocytosed bacteria. GBS avoids detection in the neonatal lung by expressing a capsule coated with sialic acid, mimicking “self” antigens in the host. Neonatal lung macrophages express very low levels of sialoadhesin, which facilitates recognition of sialic acid in the GBS capsule and bacterial killing in adults. However neonatal lung macrophages do express Siglec-E, which suppresses inflammatory signaling upon sialic acid binding. This appears to represent a fetal tolerance mechanism, as the amniotic fluid is rich in the sialic acid modified Tamm-Horsfall Protein (THP). We hypothesize that THP and sialic acid maintain immune tolerance in the fetal lung through interactions with macrophage inhibitory Siglecs. For maturation of lung macrophages, THP-sialic acid-Siglec interactions must give way to the ability to detect and kill pathogens. GBS uses its sialic acid rich capsule to mimic the effects of THP, suppressing immune activation in newborn lungs. This proposal will use novel, state of the art approaches to further investigate the molecular mechanisms regulating both immune tolerance in fetal lungs and neonatal immunity against GBS. By bringing together outstanding expertise in the Principal Investigators’ laboratories, state of the art approaches investigating development of lung immunity and mechanisms of host-microbe interactions will shed important new light on the ongoing battle between immunity and microbes around the time of birth. Collectively the aims in this proposal will identify unique molecular mechanisms that make newborns particularly susceptible to GBS pneumonia and explore new translational approaches for protecting newborns. The results will lead to development of new strategies for preventing and treating disease.

概括 胎儿和新生儿免疫系统在怀孕期间保持耐受状态。但是那一刻 婴儿是诞生的，其不成熟的免疫系统必须防御微生物的突然冲击 病原体存在于环境中。不幸的是，对于许多人来说，从公差到保护的过渡很慢， 为特定的传染性生物提供机会窗口。这种敏感性最好由小组说明 B链球菌（GBS），这是新生儿最常见的病原体，但很少导致健康疾病 成年人。新生儿首先在分娩周围暴露于GB，因为GBS经常在出生管上定居。尽管 在筛查和材料治疗方面的努力，GBS仍然是新生儿肺炎的主要原因 和早发败血症。为了发现未成熟肺中GBS感染和免疫力的机制，我们 开发了一种新型的小鼠GBS肺炎模型。成年小鼠在24小时内清除GBS，迅速解决初始 肺部炎症，并普遍存在GBS感染。但是，新生儿小鼠无法有效杀死GB， 发展持续的肺部感染和损伤，并可能死于GBS感染。巨噬细胞，第一行 成年肺的防御，新生儿不成熟，使其容易吸入和吸气细菌 包括GBS。我们的初步研究表明，未成熟的新生儿肺巨噬细胞无法安装正常 对GB的免疫反应或杀死吞噬细菌。 GBS避免在新生儿肺中检测 表达含有唾液酸的胶囊，模仿宿主中的“自我”抗原。新生儿肺巨噬细胞 表达非常低水平的唾液加密素，该设施识别GBS胶囊中的唾液酸和 成人细菌杀死。但是，新生儿肺巨噬细胞确实表达了siglec-e，它抑制了 唾液酸结合时炎症信号传导。这似乎代表了胎儿的耐受机制，因为 羊水富含唾液酸改性的tamm-Horsfall蛋白（THP）。我们假设THP和唾液 酸通过与巨噬细胞抑制性siglecs相互作用来维持胎儿肺中的免疫耐受性。为了 肺巨噬细胞的成熟，Thp-Sialic Acid-Siglec相互作用必须让位于检测和检测能力 杀死病原体。 GBS使用其唾液酸富胶囊模仿THP的作用，抑制免疫激活 在新生儿肺部。该提议将使用新颖的最新方法来进一步研究分子 调节胎儿肺免疫耐受性和针对GBS的新生儿免疫史的机制。通过带来 首席研究人员实验室的杰出专业知识，最艺术的方法 调查肺免疫学的发展和宿主 - 微生物相互作用的机制将使很重要 关于免疫和微生物之间正在进行的战斗的新灯光。集体目标 在此提案中，将确定独特的分子机制，使新生儿特别容易受到GB的影响 肺炎并探索保护新生儿的新翻译方法。结果将导致 制定预防和治疗疾病的新策略。